Browsing by Author Tardif, Jean-Claude

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 6 of 6
Issue DateTitleAuthor(s)Citation
2014Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trialNeal, Bruce; Buse, John B.; et al, .; Henry, Robert; Lincoff, A. Michael; Malmberg, Klas; Nicholls, Stephen; Ryden, Lars; Schwartz, Gregory; Tardif, Jean-Claude; Wedel, Hans; The George Institute for Global HealthEffect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial, JAMA, vol.311, 15, 2014,pp 1515-1525
2011Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFULFreedman, Saul (Ben); Ceconi, Claudio; Ferrari, Roberto; Ford, I; Fox, Kim; Gueret, P; Hildebrandt, P; McDonagh, T; Parrinello, G; Robertson, M; Steg, Ph Gabriel; Tardif, Jean-Claude; Tendera, M; Concord Clinical School: ANZAC Research InstituteEffect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL, International Journal of Cardiology, vol.146, 3, 2011,pp 408-414
2011Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) TrialBarter, Philip; Rye, Kerry-Anne; Boekholdt, S Matthijs; Breazna, Andrei; Kastelein, John J.P.; Tardif, Jean-Claude; Waters, David D; Central Clinical School: Heart Research Institute; Central Clinical School: Heart Research InstituteEffect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial, Circulation (Baltimore), vol.124, 5, 2011,pp 555-562
2007Effects of Torcetrapib in Patients at High Risk for Coronary EventsBarter, Philip; Caulfield, Mark; Eriksson, Mats; et, al; Grundy, Scott M.; Kastelein, John J.P.; Komajda, Michel; Lopez-Sendon, Jose; Mosca, Lori; Tardif, Jean-Claude; Waters, David D; Central Clinical School: MedicineEffects of Torcetrapib in Patients at High Risk for Coronary Events, New England Journal of Medicine, vol.357,(21),2007,pp 2109-2122
2013Evaluation of the dual peroxisome proliferator-activated receptor a/y agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trialNeal, Bruce; Buse, John B.; et al, Various; Henry, Robert; Lincoff, A. Michael; Malmberg, Klas; Nicholls, Stephen; Ryden, Lars; Schwartz, Gregory; Tardif, Jean-Claude; Wedel, Hans; Weichert, Arlette; The George Institute for Global HealthEvaluation of the dual peroxisome proliferator-activated receptor a/y agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial, American Heart Journal, vol.166, 3, 2013,pp 429-434.e1
2011Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trialWoodward, Mark; Abt, Markus; Ballantyne, C. M.; Burgess, Tracy; et al, various; Fayad, Zahi A; Fuster, Valentin; Kallend, David; Mani, Venkatesh; Rudd, James; Stein, Evan; Tardif, Jean-Claude; The George Institute for International HealthSafety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial, The Lancet, vol.378, 9802, 2011,pp 1547-1559